Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease

Genes (Basel). 2022 Sep 24;13(10):1715. doi: 10.3390/genes13101715.

Abstract

We investigated the presence of misfolded alpha-Synuclein (α-Syn) in minor salivary gland biopsies in relation to substantia nigra pars compacta (SNc) damage measured using magnetic resonance imaging in patients with isolated rapid eye movement sleep behavior disorder (iRBD) and Parkinson's disease (PD) as compared to healthy controls. Sixty-one participants (27 PD, 16 iRBD, and 18 controls) underwent a minor salivary gland biopsy and were scanned using a 3 Tesla MRI. Deposits of α-Syn were found in 15 (55.6%) PD, 7 (43.8%) iRBD, and 7 (38.9%) controls using the anti-aggregated α-Syn clone 5G4 antibody and in 4 (14.8%) PD, 3 (18.8%) iRBD and no control using the purified mouse anti-α-Syn clone 42 antibody. The SNc damages obtained using neuromelanin-sensitive imaging did not differ between the participants with versus without α-Syn deposits (irrespective of the antibodies and the disease group). Our study indicated that the α-Syn detection in minor salivary gland biopsies lacks sensitivity and specificity and does not correlate with the SNc damage, suggesting that it cannot be used as a predictive or effective biomarker for PD.

Keywords: Parkinson’s disease; alpha-Synuclein; immunostaining; microscopy; minor salivary gland biopsy; neuromelanin.

MeSH terms

  • Animals
  • Biomarkers
  • Mice
  • Parkinson Disease* / diagnostic imaging
  • Parkinson Disease* / pathology
  • REM Sleep Behavior Disorder* / diagnostic imaging
  • REM Sleep Behavior Disorder* / pathology
  • Salivary Glands / metabolism
  • Substantia Nigra / diagnostic imaging
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology
  • alpha-Synuclein / metabolism

Substances

  • alpha-Synuclein
  • neuromelanin
  • Biomarkers

Grants and funding

The research leading to these results received funding from a grant from the France Parkinson Association, from the French State “Investissements d’Avenir” (ANR-10-IAIHU-06), and from the EDF foundation.